Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice

Biochem Biophys Res Commun. 1994 Jul 15;202(1):543-8. doi: 10.1006/bbrc.1994.1962.

Abstract

The effect of the interleukin-1 receptor antagonist (IL-1ra) on development of hyperglycemia and insulitis in mice treated with multiple low doses of streptozotocin (STZ) was evaluated. C57BL/Ks mice were subjected to the following treatments: 1) Injections i.p. of phosphate-buffered saline (PBS) alone; 2) STZ (5 x 40 mg/kg bw); 3) STZ + PBS delivered by an osmotic pump implanted s.c; 4) STZ + IL-1ra delivered by an osmotic pump (approximately 8 mg/kg bw) for 12-14 days starting on day 5, the last day of STZ injection. IL-1ra had a clear protective action against hyperglycemia and insulitis until day 19, i.e., on cessation of IL-1ra administration. Thus, the results indicate that sustained administration of IL-1ra can prevent the diabetogenic process elicited by low dose STZ treatment, suggesting that IL-1 may have a role in the pathogenesis of this form of diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Glucose / metabolism
  • Cells, Cultured
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / pathology
  • Diabetes Mellitus, Experimental / prevention & control*
  • Dose-Response Relationship, Drug
  • Insulin / metabolism*
  • Insulin Secretion
  • Interleukin 1 Receptor Antagonist Protein
  • Islets of Langerhans / drug effects*
  • Islets of Langerhans / metabolism
  • Islets of Langerhans / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Interleukin-1 / antagonists & inhibitors*
  • Reference Values
  • Sialoglycoproteins / pharmacology*
  • Streptozocin / administration & dosage
  • Time Factors

Substances

  • Blood Glucose
  • Il1rn protein, mouse
  • Insulin
  • Interleukin 1 Receptor Antagonist Protein
  • Receptors, Interleukin-1
  • Sialoglycoproteins
  • Streptozocin